The insulin infusion pump market is expected to further boom in the future with projections suggesting a jump to $10.31 billion by 2029, riding a CAGR of 10.2%.

Medtronic and some other older, discontinued tubed pump brands have a cylinder reservoir that holds the insulin, with the infusion needle housed in a small part on top.

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.

Much of the responsibility for ensuring safety is therefore delegated to the pump companies themselves (including companies that provide insulin infusion sets [IISs] and insulin products).

The companies will offer their engineering and development know-how to bring the patch pump to the market.

Oct. 3, 2018 Artificial pancreas has edge over insulin pump therapy in study Stryker settles foreign corrupt practice charges, makes small acquisition Oct. 2, 2018 FDA, ECRI, device group keep up ...

MedTech industry newsElise Reuter Senior Reporter | @EliseReuter Elise has spent most of her career writing about healthcare and technology for business publications. She was a data fellow for USC ...